The global industry award recognizes Adaptimmune’s achievements in the exciting and competitive immunotherapy space.
“This was a banner financing, especially for a
Adaptimmune’s strategic goal is to bring breakthrough therapies to cancer patients, and the company is conducting Phase 1/2 clinical trials of its affinity-enhanced NY-ESO TCR therapeutic candidate in patients with synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and non-small cell lung cancer. The company is developing its NY-ESO-1 therapy under a collaboration agreement with GlaxoSmithKline.
“We are delighted to win this 2015 Scrip Award - it is a tribute to years of work by a dedicated team to develop our innovative immunotherapies, which enabled us to attract financing from leading U.S. funds and complete the IPO,” said
Adaptimmune’s next affinity enhanced T-cell therapy directed at MAGE A-10, one of a number of proprietary programs, is scheduled to enter the clinic shortly. In addition, the company has also recently announced a collaboration with
The annual Scrip awards, which are in their 11th year, acknowledge and applaud the biotechnology and pharmaceutical industry’s highest achievers and are open to any research-based pharmaceutical or biotechnology company as well as third party companies that supply services to the pharmaceutical industry. A complete list of award winners is available at: www.scripawards.com
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the
Will RobertsVice President, Investor Relations T: (215) 825 9306 E: firstname.lastname@example.org Margaret HenryHead of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: email@example.com